Bristol Myers Squibb (BMY) Rises Higher Than Market: Key Facts
https://www.zacks.com/stock/news/2246994/bristol-myers-squibb-bmy-rises-higher-than-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2246994
Mar 27, 2024 - In the most recent trading session, Bristol Myers Squibb (BMY) closed at $53.25, indicating a +1.33% shift from the previous trading day.
0
Bristol Myers (BMY) Wins EC Nod for Reblozyl Label Expansion
https://www.zacks.com/stock/news/2249839/bristol-myers-bmy-wins-ec-nod-for-reblozyl-label-expansion?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2249839
Apr 03, 2024 - Bristol Myers (BMY) receives European Commission's approval for a label expansion of Reblozyl (luspatercept) for another indication.
0
Bristol Myers Squibb (BMY) Advances While Market Declines: Some Information for Investors
https://www.zacks.com/stock/news/2255656/bristol-myers-squibb-bmy-advances-while-market-declines-some-information-for-investors?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6v1-2255656
Apr 15, 2024 - Bristol Myers Squibb (BMY) closed the most recent trading day at $48.51, moving +0.48% from the previous trading session.
0
2seventy bio (TSVT) Rises More Than 50% in 3 Months: Here's Why
https://www.zacks.com/stock/news/2257012/2seventy-bio-tsvt-rises-more-than-50-in-3-months-here-s-why?cid=CS-ZC-FT-analyst_blog|price_surge_/_plunge-2257012
Apr 17, 2024 - The FDA's recent nod to 2seventy bio's (TSVT) Abecma in earlier lines of treatment for relapsed/refractory multiple myeloma is a positive. Also, the R&D asset divestiture to Regeneron is saving costs.
0
2 High-Yield Dividend Stocks to Buy and Hold for 10 Years
https://www.fool.com/investing/2024/04/17/2-high-yield-dividend-stocks-to-hold-for-10-years/?source=iedfolrf0000001
Apr 17, 2024 - These income stocks look like good options at current levels.
0
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
https://www.zacks.com/stock/news/2218010/amgen-amgn-earnings-expected-to-grow-what-to-know-ahead-of-next-week-s-release?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_9-2218010
Jan 30, 2024 - Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
0
Bristol Myers' (BMY) sBLAs for Breyanzi Get FDA Priority Tag
https://www.zacks.com/stock/news/2218934/bristol-myers-bmy-sblas-for-breyanzi-get-fda-priority-tag?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2218934
Jan 31, 2024 - Bristol Myers' (BMY) two sBLAs for Breyanzi in relapsed/refractory follicular lymphoma and relapsed/refractory mantle cell lymphoma receive FDA acceptance and priority review.
0
Bristol Myers Squibb (BMY) Q4 2023 Earnings Call Transcript
https://www.fool.com/earnings/call-transcripts/2024/02/02/bristol-myers-squibb-bmy-q4-2023-earnings-call-tra/?source=iedfolrf0000001
Feb 02, 2024 - BMY earnings call for the period ending December 31, 2023.
0
Compared to Estimates, Bristol Myers (BMY) Q4 Earnings: A Look at Key Metrics
https://www.zacks.com/stock/news/2220250/compared-to-estimates-bristol-myers-bmy-q4-earnings-a-look-at-key-metrics?cid=CS-ZC-FT-fundamental_analysis|nfm-2220250
Feb 02, 2024 - While the top- and bottom-line numbers for Bristol Myers (BMY) give a sense of how the business performed in the quarter ended December 2023, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
0
Bristol Myers (BMY), TSVT CAR T-Cell Therapy to Face FDA's ODAC
https://www.zacks.com/stock/news/2221922/bristol-myers-bmy-tsvt-car-t-cell-therapy-to-face-fda-s-odac?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-2221922
Feb 06, 2024 - Bristol Myers (BMY) and its partner TSVT announce that the FDA's ODAC will meet in March to review data supporting the label expansion for CAR T-cell therapy.
0
<Page 2